Скачать с ютуб 【Angiogenesis Inhibitors】Bevacizumab, Ramucirumab, Sorafenib, Sunitinib, Pazopanib, Regorafenib в хорошем качестве

【Angiogenesis Inhibitors】Bevacizumab, Ramucirumab, Sorafenib, Sunitinib, Pazopanib, Regorafenib

Do you know about Vascular Endothelial Growth Factor (VEGF)? It promotes blood vessel growth. Why is VEGF-VEGFR pathway used for targeted- cancer treatment? How does angiogenesis inhibitors work? What is multi-kinase inhibitors? Learn about Bevacizumab (Alymsys®, Mvasi®, Avastin®, Zirabev®), Ramucirumab (Cyramza®), Sorafenib (Nexavar®), Sunitinib (Sutent®), Pazopanib (Votrient®), Regorafenib (STIVARGA®). #targetedtherapy #bloodvessels #cancertreatment 【Study Break Oasis】 5-Min Forest Oasis: Healing Sounds for Study Stress    • 5-Min Forest Oasis: Healing Sounds fo...   5-Min Seaside Serenity: Waves of Calmness for Study Stress    • 5-Min Seaside Serenity: Waves of Calm...   【Notes】 ▹This video was created based on data as of January 2024, with the purpose of supporting medical students in their exam preparations. ▹It is not a substitute for medical advice. ▹Please note that thanks to the tireless efforts of researchers worldwide, this data is updated daily. ▹Unauthorized reproduction is prohibited. 【Contents】 00:00 What is VEGF (Vascular Endothelial Growth Factor)? 00:47 VEGF and VEGF-Receptor pathway, Why is this system used in cancer treatment? 01:30 Angiogenesis Inhibitors-1) Monoclonal antibodies: Bevacizumab and Ramucirumab 02:23 Angiogenesis Inhibitors-2) Tyrosine Kinase Inhibitors? 03:07 Sorafenib, Sunitinib, Pazopanib, Regorafenib. They have some distinctive features. 03:18 What is the difference?: Multi-targeted tyrosine kinase inhibitors. 04:18 Adverse Effect of Angiogenesis inhibitors. Hypertension? 【Reference and figure】 I express my gratitude and respect for your wonderful achievements. 1. Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NB... 2. Olsson, AK., Dimberg, A., Kreuger, J. et al. VEGF receptor signalling ? in control of vascular function. Nat Rev Mol Cell Biol 7, 359–371 (2006). https://doi.org/10.1038/nrm1911 3. NIH National Cancer Institute, A to Z List of Cancer Drugs, “Bevacizmab”. https://www.cancer.gov/about-cancer/t... 4. NIH National Cancer Institute, A to Z List of Cancer Drugs, “Ramucirumab”. https://www.cancer.gov/about-cancer/t... 5. NIH National Cancer Institute, NCI Dictionary of Cancer terms, “kinase inhibitor”. https://www.cancer.gov/publications/d... 6. NIH National Cancer Institute, A to Z List of Cancer Drugs, “Sorafenib”. https://www.cancer.gov/about-cancer/t... 7. Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: sorafenib pathways. Pharmacogenet Genomics. 2017 Jun;27(6):240-246. doi: 10.1097/FPC.0000000000000279. PMID: 28362716; PMCID: PMC5418090. 8. Hasskarl J. Sorafenib: targeting multiple tyrosine kinases in cancer. Recent Results Cancer Res. 2014;201:145-64. doi: 10.1007/978-3-642-54490-3_8. PMID: 24756790. 9. DRUGBANK Online, Sunitinib, DB01268 https://go.drugbank.com/drugs/DB01268 10. Mohammed Gabr Kassem, A.F.M. Motiur Rahman, Hesham M. Korashy, Chapter 9 - Sunitinib Malate, Editor(s): Harry G. Brittain, Profiles of Drug Substances, Excipients and Related Methodology, Academic Press, Volume 37, 2012, Pages 363-388, ISSN 1871-5125, ISBN 9780123972200, https://doi.org/10.1016/B978-0-12-397.... (https://www.sciencedirect.com/science...) 11. NIH National Library of Medicine, COMPOUND SUMMARY, “Pazopanib”, PubChem CID 10113978. https://pubchem.ncbi.nlm.nih.gov/comp... 12. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35. PMID: 19037839. 13. NIH National Cancer Institute, A to Z List of Cancer Drugs, “Regorafenib”. https://www.cancer.gov/about-cancer/t... 14. Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, Zhang D, Guo H, Shi B. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2014 Mar;16(3):177-85. doi: 10.1111/jch.12273. PMID: 24621095; PMCID: PMC8031967.